What Is Orticumab?
Orticumab is a medication classified as a human recombinant monoclonal antibody. This type of drug is specifically designed to target and bind to certain substances in the body. In the case of Orticumab, it targets a specific epitope on oxidized low-density lipoprotein (oxLDL). By binding to oxLDL, Orticumab is thought to potentially help reduce inflammation and may influence disease processes where oxLDL plays a significant role.
Orticumab is currently an investigational drug, meaning it is being studied in clinical trials to determine its safety and effectiveness. It is being explored for its potential therapeutic benefits in various conditions, including inflammation, atherosclerotic coronary vascular disease, and coronary artery disease. Studies are also investigating its use in patients who have experienced a myocardial infarct, as well as for cardiometabolic syndrome and psoriasis. There are currently 2 clinical trials involving Orticumab, with a total enrollment of 317 participants. The first trial began in 2021, and the latest is expected to conclude in 2025.
Uses and Conditions Under Study
Orticumab is currently being investigated in clinical trials for a range of conditions, primarily focusing on inflammation and cardiovascular diseases.
One key area of study is inflammation, which is being explored in 2 trials. Inflammation is the body's response to injury or infection, but chronic inflammation can contribute to many diseases. Given Orticumab's mechanism of targeting oxidized low-density lipoprotein (oxLDL), which is implicated in inflammatory processes, it is being studied for its potential to modulate these responses.
Several cardiovascular conditions are also under investigation. These include Atherosclerotic Coronary Vascular Disease, Coronary Arterial Disease (CAD), and Coronary Artery Disease, which all relate to the narrowing or blockage of the heart's arteries due to plaque buildup. Orticumab's ability to target oxLDL, a key component of atherosclerotic plaques, suggests it could play a role in managing these conditions. Additionally, it is being studied for Heart Disease, Myocardial Infarct (heart attack), and Acute Coronary Syndromes, which represent severe forms of heart disease often linked to atherosclerosis and inflammation. Cardiometabolic Syndrome, a cluster of conditions that increase the risk of heart disease, stroke, and type 2 diabetes, is also being explored. In total, these cardiovascular conditions are being studied across multiple trials, with one trial specifically focusing on post-myocardial infarction populations.
Finally, Psoriasis is another condition for which Orticumab is being investigated. Psoriasis is a chronic autoimmune disease characterized by rapid skin cell turnover, leading to red, scaly patches. As an inflammatory condition, the potential anti-inflammatory effects of Orticumab may offer a new therapeutic approach for patients with psoriasis.
Dosing
Clinical trials investigating Orticumab have explored different dosage approaches to determine the most effective and safe treatment regimens. The studies have specifically examined varying levels of the drug, referred to as Orticumab High Dose and Orticumab Low Dose. These different dose levels are being evaluated to understand their impact on conditions such as inflammation and post-myocardial infarction populations.
One trial description mentions "Orticumab treatment for 24 weeks for post MI population," indicating a specific duration of therapy being studied for patients who have experienced a heart attack. While the specific method of administration (e.g., oral, injection) is not detailed in the provided trial information, the investigation into distinct high and low doses suggests a careful assessment of the drug's pharmacokinetic and pharmacodynamic properties. The trials aim to identify the optimal dosing strategy for Orticumab across the various conditions it is being studied for, including atherosclerotic coronary vascular disease, coronary artery disease, and psoriasis. Further research will clarify the precise dosing recommendations for Orticumab if it becomes available.
Side Effects
The most common side effect reported in clinical trials for Orticumab was headache. In one study involving 52 patients taking Orticumab, 5.8% experienced headaches, compared to 8.0% of patients taking a placebo.
Clinical Trial Results
Results for Orticumab come from a proof-of-activity study (NCT04776629) in patients with psoriasis and cardiometabolic risk factors.
Psoriasis Symptoms and Quality of Life
Patients treated with Orticumab experienced greater improvements in psoriasis severity and quality of life compared to those on placebo:
- On average, patients taking Orticumab saw their Dermatology Life Quality Index (DLQI) score improve by 3.75 points, indicating a better quality of life. Patients on placebo improved by 2.43 points.
- The Psoriasis Area Severity Index (PASI) score, which measures the severity and extent of psoriasis, improved by an average of 16.9% in patients receiving Orticumab. For those on placebo, the PASI score improved by an average of 9.7%.
- The percentage of body surface area (BSA) affected by psoriasis also showed greater improvement with Orticumab, with an average reduction of 10.2% in affected BSA. Patients on placebo saw an average reduction of 4.2%.
Coronary Artery Health
The study also looked at markers of coronary artery health:
- Changes in coronary artery inflammation, as measured by CCTA, generally showed reductions in patients treated with Orticumab, while patients on placebo generally experienced increases in inflammation.
- Regarding coronary artery plaque burden, median changes were generally smaller or showed no increase in patients receiving Orticumab compared to those on placebo, which often showed larger increases.
Currently Recruiting Trials
Orticumab is currently being investigated in clinical trials to understand its potential benefits for patients facing specific health challenges. These studies are crucial steps in determining if orticumab can effectively treat certain conditions by targeting underlying biological processes, particularly inflammation, which plays a key role in many diseases.
One significant study actively recruiting participants is NCT06927739, titled "Focused Orticumab Research for Treating Inflammation in Coronary Arteries." This Phase 2 clinical trial, sponsored by Abcentra, is specifically designed to evaluate the clinical effect of orticumab treatment on inflammation in the coronary arteries. The study focuses on individuals who have previously experienced a myocardial infarction (heart attack) and have elevated coronary inflammation, as identified through CCTA imaging. The main question this trial aims to answer is how orticumab treatment impacts inflammation in these patients. This research is vital for understanding potential new treatments for a range of cardiovascular conditions, including Acute Coronary Syndromes, Coronary Arterial Disease (CAD), Heart Disease, Myocardial Infarct, and Atherosclerotic Coronary Vascular Disease. By studying orticumab's effect on inflammation, researchers hope to find new ways to manage and improve outcomes for these serious conditions. Participants will be assigned to receive either an Orticumab High Dose or an Orticumab Low Dose, allowing researchers to compare the effects of different treatment levels. The trial is seeking to enroll approximately 240 individuals to gather comprehensive data on the drug's effects across these important cardiovascular conditions.
Where to Participate
The "Focused Orticumab Research for Treating Inflammation in Coronary Arteries" trial (NCT06927739) is currently recruiting participants across one site, spanning seven cities and six states in the United States. This broad reach aims to provide opportunities for eligible individuals in various regions to contribute to this important research.
Top participating locations include:
- Los Angeles, California
- Torrance, California
- Boca Raton, Florida
- Richmond, Indiana
- Louisville, Kentucky
- Baltimore, Maryland
- Midland, Michigan
To be eligible for this study, participants must be between 18-18 years of age. The trial is open to all genders, but it is not seeking healthy volunteers; participants must have a prior myocardial infarction and elevated coronary inflammation. Children are not eligible to participate.
Development Timeline
The journey of Orticumab began with its first clinical trial initiated on March 2, 2021, marking the start of its development by Abcentra. From its inception, Abcentra has been the sole sponsor driving the research and progression of Orticumab through clinical phases.
Initially, Orticumab's development focused on conditions such as IBS-C and hyperphosphatemia. However, the research pipeline for Orticumab has significantly expanded over time, reflecting a growing understanding of its potential therapeutic applications. The drug's investigation broadened to include a range of cardiometabolic and inflammatory conditions. This expansion now encompasses Cardiometabolic Syndrome, Coronary Arterial Disease (CAD), Coronary Artery Disease, Heart Disease, Myocardial Infarct, Acute Coronary Syndromes, and Psoriasis.
To date, a total of two clinical trials have been conducted for Orticumab, collectively enrolling 317 participants. Both of these studies have progressed to Phase 2, indicating that Orticumab is currently undergoing mid-stage evaluation to assess its effectiveness and safety in a larger group of patients. The latest recorded trial activity for Orticumab is set to conclude on April 15, 2025, highlighting the ongoing commitment to understanding its full potential.